Countless preclinical- and clinical-stage drugs remain shelved, not for scientific reasons or because they lack demonstrated potential to help patients, but rather because of strategic, organizational, financial, and/or other resource-prioritization decisions. Meanwhile, there are companies and organizations that are willing to take the risk, and expend the resources and effort, to advance these shelved assets, either for continued development in the same therapeutic area or repositioning the asset to pursue a new indication. This panel of experts will explore how we can create opportunities for interested companies and organizations to gain access to drugs with the potential to help patients, drawing from their own unique experiences advancing previously shelved assets to address significant unmet patient needs.